Company profile image

Doc Generici

National flag images

Italy

Founded in

1996 (29 Years)

Founded

Last online: No recent activity


No Review

Not enough to calculate score

Verification on TrustFinance icon

Verification on TrustFinance

0.00

Traffic & Engagement icon

Traffic & Engagement

2.67

This company no score yet, be the first to review

Trustfinance icon

Provided by TrustFinance

A

AFDA B.V.

no review

N/A

N/A

Security Information :

Company hasn't provided information.

Security Information

    Note icon

    What are the differences in regulations for each

    License

    A Grade License

    Issued by globally renowned regulators, these licenses ensure the highest trader protection through strict compliance, fund segregation, insurance, and regular audits. Dispute resolution and adherence to AML/CTF standards further enhance security.

    B Grade License

    Granted by respected regional regulators, these licenses offer robust safety measures such as fund segregation, financial reporting, and compensation schemes. Though slightly less strict than Tier 1, they provide dependable regional protection.

    C Grade License

    Issued by regulators in emerging markets, these licenses offer basic protections such as minimum capital requirements and AML policies. Oversight is less stringent, so traders should exercise caution and verify safety measures.

    D Grade License

    From jurisdictions with minimal oversight, these licenses often lack key protections like fund segregation and insurance. While attractive for operational flexibility, they pose higher risks to traders.

    building-icon

    Company Information

    Get to know Doc Generici

    DOC Generici was founded in 1996 following the passing of law 425 of 8 August that year, which approved the use of equivalent medicines. The company was created by the joint efforts of three pharmaceutical groups: Chiesi Farmaceutici, Zambon and the Canadian group Apotex, market leader in America in the production and distribution of equivalent medicines. Distribution started for real in 2001 when, following approval of law 405 of 16 November of that year, pharmacists became obliged to provide an equivalent medicine with the lowest price amongst those available on the normal regional distributive network, whenever a doctor prescribes a medicine without specifying that it is not to be substituted. Between 1996 and 2001 DOC Generici laid down the managerial, organizational and manufacturing foundations that enabled it to be among the first to enter the equivalent medicines market. On July 1st 2013 DOC Generici was acquired by Charterhouse Capital Partners LLP, a British Private Equity Fund and one of Europe's leading Private Equity Firms. This is the first investment in Italy by this large and historical Fund. The acquisition will allow DOC Generici to keep its independence and to continue its investment in the key objectives of its success: endorse Europe and especially Italy for manufacturing of generic medicinal products, prevent speculation on quality in favor of cost and keep a high level of communication.

    Industry

    • Financial BankingPRIMARY

    Contact

    location-contact-icon

    -

    website-contact-icon

    -

    phone-contact-icon

    -

    email-contact-icon

    -

    Social

    Company hasn't updated its information.

    Social scout image

    Social Scout

    See what Social Scout found of Doc Generici

    Trustfinance icon

    Provided by TrustFinance AI Analysis

    Reviews

    Total 0

    Review analysis image

    AI Review analysis

    Let’s TrustFinance AI Summarize all the reviews for you.

    Trustfinance icon

    Provided by TrustFinance AI Analysis

    Filter

    5 Star

    0%

    4 Star

    0%

    3 Star

    0%

    2 Star

    0%

    1 Star

    0%

    Sort by